劑泰醫(yī)藥（METiS）是一家生物技術(shù)公司，由美國(guó)工程院院士和多位MIT科學(xué)家領(lǐng)銜，獲峰瑞、紅杉、源碼、光速、五源、招銀國(guó)際、中國(guó)人保和中國(guó)人壽等資本支持，旨在通過(guò)將藥物發(fā)現(xiàn)和藥物遞送與人工智能、機(jī)器學(xué)習(xí)和量子模擬相結(jié)合，提高藥物生物可利用度、穩(wěn)定性以及開(kāi)發(fā)新劑型、新載體系統(tǒng)，在廣大疾病領(lǐng)域推動(dòng)最佳療法。同時(shí)，聚焦于KCE/NCE、核酸藥、505b2研發(fā)，以滿足臨床需求。
METiS Pharmaceuticals is a biotechnology company that is led by academicians of National Academy of Engineering and a number of MIT scientists,with the capital support of FreesFund, Sequoia, Sourcecode, Lightspeed, 5Y Capital,CMBI,China Life and PICC,etc.By integrating drug discovery and delivery with AI, machine learning, and quantum simulation,METiS pharmaceuticals aims to increase bioavailability, stability and to develop new dosage forms,new carrier system in order to drive best-in-class therapies in a wide range of disease areas.At the same time, to meet clinical needs, METiS is focusing on the development of KCE/NCE，RNA and 505b2.?